Ted Dawson
Scientist
VS
Valted Seq
Valted Seq is a biopharmaceutical company utilizing the world's largest repository of single-cell sequencing data to identify novel biomarkers and therapeutic pathways for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. By applying advanced big data analytics, the company aims to enhance precision therapeutics and improve patient outcomes in these challenging conditions.
- Artificial Intelligence
- Data & Analytics
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$13MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Valina Dawson
Scientist
Product
Problem
Developing effective treatments for neurodegenerative diseases like Alzheimer's and Parkinson's is hindered by an incomplete understanding of the underlying biological mechanisms and a lack of reliable biomarkers for early diagnosis and monitoring. Traditional drug discovery approaches often fail due to the complexity of these diseases and the difficulty of identifying relevant therapeutic targets.
Solution
Valted Seq leverages a large, proprietary repository of single-cell sequencing data to identify novel biomarkers and therapeutic pathways for neurodegenerative diseases. By applying advanced big data analytics and machine learning techniques to this unique dataset, the company aims to uncover previously unknown disease mechanisms and develop more targeted and effective therapies. Their approach focuses on enhancing precision therapeutics by identifying patient subgroups that are most likely to respond to specific treatments, ultimately improving patient outcomes in these challenging conditions. The company seeks to translate these discoveries into clinically relevant diagnostic tools and therapeutic interventions.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and clinicians focused on developing and delivering treatments for neurodegenerative diseases.
Features
- World's largest repository of single-cell sequencing data for neurodegenerative diseases
- Advanced big data analytics platform for identifying novel biomarkers and therapeutic pathways
- Machine learning models for predicting disease progression and treatment response
- Focus on precision therapeutics tailored to specific patient subgroups
- Identification of novel drug targets based on single-cell sequencing data